Business Wire

CA-ALATION/BIGEYE/SODA

7.12.2021 15:02:09 CET | Business Wire | Press release

Share
Alation Forges Strategic Partnerships With Bigeye and Soda

Alation, Inc. , the leader in enterprise data intelligence solutions, today announced formal partnership agreements with Bigeye and Soda , leading data observability vendors. The partnerships provide customers with the choice to select the best data observability partner for their organisation’s needs.

Alation’s active data governance helps organisations drive data culture by providing all data users, regardless of technical skillset, with access to quality data. Bigeye’s data observability platform helps detect data quality issues and ensures reliable data pipelines. Soda’s data observability platform allows teams to discover, prioritise, and collaboratively resolve data issues. The platforms are invaluable for alerting technical users to deeper data quality issues, such as the trustworthiness of the data or its usability. Alation’s integrations with Bigeye and Soda provide all data consumers, from business users to data scientists, with a single-pane-of-glass view into the trustworthiness and reliability of data. This results in a streamlined analysis process that empowers data users to use data and generate insights with confidence.

“When it comes to data intelligence and data governance, Alation has long catered to the needs of every user, not just the technical user. Our customers see Alation as the primary source of reference for all metadata, which enables all teams across an organisation to make data-driven business decisions,” said Raj Gossain, Chief Product Officer, Alation. “The Alation Data Catalog is a platform known for its interoperability. With our APIs and partnerships, we continue to expand the ecosystem of companies that work with Alation, giving our customers a modern user experience that seamlessly integrates best-of-breed solutions that meet their needs.”

Fuelled by exponential data growth and expanding privacy regulations, data governance is a top priority for enterprises. Traditional approaches to data governance have long focused on restrictive data policies and procedures that hinder adoption and result in additional challenges for those responsible for the data. Effective data governance programs must focus on enabling users to leverage trusted, governed data to make informed, data-driven decisions. Organisations using an active, people-first approach to data governance, drive data culture and put quality data, not just any data, in everyone’s hands.

“A key part of ensuring data quality and reliable data pipelines is the ability to keep data teams and data consumers on the same page. With the integration between Alation and Bigeye, everyone — from data engineers all the way to business analysts — has a clear understanding of the health of the data,” said Egor Gryaznov, CTO and cofounder, Bigeye. “Pairing the leading data observability platform with Alation’s leading data catalog provides organisations with a holistic view of the quality of their data.”

“The modern data catalog is becoming a real-time, operational system that's deeply tied into an organisation’s data ecosystem. For metadata, that means it is purposefully built into every step of the data value chain, as opposed to it being an afterthought. This allows data teams to truly see what's happening so that they can catch data issues before they reach consumers downstream,” explains Maarten Masschelein, CEO and Co-Founder, Soda. “Through our partnership with Alation, users can discover and understand the data that matters to them, and trust they are working with data that is verified, reliable, and governed. Soda enables data producers and consumers to agree on what good data looks like by combining both machine learning-based alerting, as well as rules-based testing and validation of data. Every single operational metadata quality issue that Soda captures, can be made natively available in the Alation Data Catalog. We layer our data quality controls on top of Alation’s automated lineage to make it easy to do Root Cause Analysis (RCA), as well as assess the upstream and downstream impact of a data issue.”

To learn more about Alation’s partnerships with Bigeye and Soda:

About Alation
Alation is the leader in enterprise data intelligence solutions including data search & discovery, data governance, data stewardship, analytics, and digital transformation. Alation’s initial offering dominates the data catalog market. Thanks to its powerful Behavioral Analysis Engine, inbuilt collaboration capabilities, and open interfaces, Alation combines machine learning with human insight to successfully tackle even the most demanding challenges in data and metadata management. More than 300 enterprises drive data culture, improve decision making, and realise business outcomes with Alation including AbbVie, American Family Insurance, Cisco, Exelon, Fifth Third Bank, Finnair, Munich Re, NASDAQ, New Balance, Parexel, Pfizer, US Foods and Vistaprint. Headquartered in Silicon Valley, Alation was named to Inc. Magazine’s Best Workplaces list and is backed by leading venture capitalists including Blackstone, Costanoa, Data Collective, Dell Technologies, Icon, ISAI Cap, Riverwood, Salesforce, Sanabil, Sapphire, and Snowflake Ventures. For more information, visit alation.com .

About Bigeye
Bigeye is the leading data observability platform designed to help data teams build trust in data. Data teams use Bigeye to instrument their data with monitoring, detect anomalies, and publish SLAs for their stakeholders to know the health of the data at all times and ensure reliable data pipelines. Complete API access, a user-friendly interface, and flexible customisation options help data teams work the way they want to. Bigeye can be deployed in as little as 15 minutes and uses automation and anomaly detection to help teams monitor all aspects of their data quality, proactively detect and resolve issues, and ensure that every user can trust the data. www.bigeye.com

About Soda
Soda is the data monitoring platform that keeps your data fit for purpose, verifiable and trustworthy. We uncover data issues, alert the right teams, and trigger resolution workflows to identify causes that impede data quality. Our open source testing projects and monitoring platform brings together data engineers, operations and the business to create trusted data. Data-driven organisations choose Soda to realise the value of their data and secure its quality. For more information, visit www.soda.io .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye